Disruptive and differentiated technology

• We are developing the first neuroprotective therapy for glaucoma designed to halt retinal neurodegeneration, addressing the underlying cause of the disease and not only intraocular pressure. Because glaucoma is not caused solely by intraocular pressure, but also by neurodegenerative processes that continue to damage the retina even when pressure is under control. There is currently no approved therapy with this approach.
• Cilastatin is a molecule with more than 30 years of clinical use in humans, which significantly reduces the development risk compared with new chemical entities.

Solid scientific validation

• Robust preclinical proof of concept in the reference model for glaucoma, with results published in an international peer-reviewed scientific journal in 2024.
• Results demonstrating neuroprotection of retinal ganglion cells independently of the reduction of intraocular pressure.

Strong intellectual property

• International patent protecting the technology until 2043, with new applications in preparation to extend commercial exclusivity even further.

Major market opportunity

• Global glaucoma market estimated at USD 11.5 billion in 2030, with annual growth of 4.6%.
• More than 185 million people affected by glaucoma and an absence of treatments capable of halting the progression of the disease.

Upcoming high-value milestones

• Less than 12 months to reach First-in-Human and advance toward clinical proof of concept in patients.
• Program at an advanced stage of development with the ophthalmic formulation, pharmacokinetic studies, CMC activities and regulatory studies already completed or underway.

Validated business model and return potential

• Strategy based on licensing to large ophthalmology pharmaceutical companies after demonstrating clinical efficacy.
• Model already validated through a previous international license with Arch Biopartners for another cilastatin-based indication. This agreement allowed Telara to transfer the development and commercialization rights to a specialized partner, while retaining economic rights associated with milestones and royalties.
• Exit target around 2030, with comparable transactions in ophthalmology supporting valuations above €150M.
• Licensing and acquisition precedents in ophthalmology: the acquisition of Aerie Pharmaceuticals by Alcon in 2022 closed at approximately USD 770 million, while the regional license of Rhopressa/Rocklatan between Santen and Aerie reached USD 165 million in 2021. Analyzing a broader set of comparable transactions in ophthalmology and retina, Telara estimates an average transaction value of approximately USD 338 million, rising to USD 467.5 million for assets specifically targeting glaucoma.

Team and recognition

• Founding team with extensive experience in drug development, ophthalmology and the creation of biotechnology companies.
• Recent awards: Best Project Keiretsu Forum 2025, ENISA Empresa Emergente certification, Top 5 Innovator's Pitch Challenge (RESI Europe) and Biotechnology & Lifesciences Awards 2025.

In summary: Telara Pharma combines innovative technology with solid scientific validation, intellectual property protected until 2043, a multi-billion market, a defined regulatory pathway and a clear exit strategy, offering a unique opportunity to invest in a potential future leader in ophthalmic neuroprotection.